Title
Oral sampling methods are associated with differences in immune marker concentrations
Date Issued
01 June 2018
Access level
open access
Resource Type
journal article
Author(s)
Fakhry C.
Qeadan F.
Yori P.
Patterson N.
Eisele D.W.
Gourin C.G.
Chitguppi C.
Marks M.
Gravitt P.
Publisher(s)
John Wiley and Sons Inc.
Abstract
Objective: To determine whether the concentration and distribution of immune markers in paired oral samples were similar. Study Type: Clinical research. Study Design: Cross-sectional study. Methods: Paired saliva and oral secretions (OS) samples were collected. The concentration of immune markers was estimated using Luminex multiplex assay (Thermo Fisher Scientific, Waltham, MA). For each sample, the concentration of respective immune markers was normalized to total protein present and log-transformed. Median concentrations of immune markers were compared between both types of samples. Intermarker correlation in each sampling method and across sampling methods was evaluated. Results: There were 90 study participants. Concentrations of immune markers in saliva samples were significantly different from concentrations in OS samples. Oral secretions samples showed higher concentrations of immunoregulatory markers, whereas the saliva samples contained proinflammatory markers in higher concentration. Conclusion: The immune marker profile in saliva samples is distinct from the immune marker profile in paired OS samples. Level of Evidence: 2b. Laryngoscope, 128:E214–E221, 2018.
Start page
E214
End page
E221
Volume
128
Issue
6
Language
English
OCDE Knowledge area
InmunologÃa
Subjects
Scopus EID
2-s2.0-85035031926
PubMed ID
Source
Laryngoscope
ISSN of the container
0023852X
Sponsor(s)
Thesis number: 2016-2. We would like to acknowledge study participants for their participation. We would also like to acknowledge Maribel Paredes Olortegui, Alberto Mejia Medrano, Dixner R. Trigs, Sarah Qureshi, Christine Huang for their invaluable contributions.
This study was supported by the National Cancer Institute (grant R21 CA156537 to P.G.) and the Johns Hopkins Center for Global Health (GHEFP Program, Qureshi). We acknowledge the University of New Mexico Clinical & Translational Science Center (CTSC) (grant UL1TR001449) and the Mountain West Clinical Translational Research Infrastructure Network (grant 1U54GM104944). University of New Mexico Health Sciences Center (Albuquerque, New Mexico). We also acknowledge the support of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine (Baltimore, Maryland) and Oral Cancer Foundation. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
Sources of information:
Directorio de Producción CientÃfica
Scopus